Inhibitory effect of nicotine and its metabolites on tolbutamide hydroxylation in rat liver microsomes

Journal of Biochemical and Biophysical Methods

Volumn 36, Issue 2-3, 1998, Pages 87-94

  Leung, Yuet Kin ^a   Ho, John W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HPLC fluorescence detection; Metabolism; Microsomes; Nicotine; Nornicotine; Tolbutamide

Indexed keywords

HYDROXYTOLBUTAMIDE; NICOTINE; NORNICOTINE; TOLBUTAMIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG HYDROXYLATION; DRUG METABOLISM; EXTRACTION; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COTININE; FLUORESCENCE; HYDROXYLATION; HYPOGLYCEMIC AGENTS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NICOTINE; RATS; SENSITIVITY AND SPECIFICITY; SMOKING; TOLBUTAMIDE;

EID: 0031778762     PISSN: 0165022X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-022X(98)00003-7     Document Type: Article

References (27)

1. Gee S.J., Green C.E., Tyson C.A. Comparative metabolism of tolbutamide by isolated hepatocytes from rat, rabbit, dog, and squirrel, monkey. Drug Metab. Dispos. 12:1984;174-178.
2. Back D.J., Tija J., Monig H., Ohnhaus E.E., Park B.K. Selective inhibition of drug oxidation after simultaneous adminstration of two probe drugs, antipyrine and tolbutamide. Eur. J. Clin. Pharmacol. 34:1988;157-163.
3. Miners J.O., Foenander T., Wanwimolruk S., Gallus A.S., Birkett D.J. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. Eur. J. Clin. Pharmacol. 22:1982;321-326.
4. Dey N.G., Castleden C.M., Ward J., Cornhill J., McBurney A. The effect of cimetidine on tolbutamide kinetics. Br. J. Clin. Pharmacol. 16:1983;438-440.
5. Ho J.W., Moody D.E. Determination of tolbutamide hydroxylation in rat liver microsomes by high-performance liquid chromatography: Effects of psychoactive drugs on in vitro activity. Life Sci. 52:1993;21-28.
6. Jones B.C., Hawksworth P., Horne V.A., Newlands A. Putative active site template model for cytochrome P450 2C9 (tolbutamide hydroxylase). Drug Metab. Dispos. 24:1996;260-266.
7. Miners J.O., Birkett D.J. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol. 272:1996;139-145.
8. Shibasaki J., Konishi R., Ueki T., Morishita T. Drug absorption, metabolism, and excretion. 8. Determination of tolbutamide and its metabolites in blood and urine. Chem. Pharm. Bull. 21:1973;1747-1753.
9. Back D.J., Sutcliffe F., Tija J.F. Tolbutamide as a model-drug for the study of enzyme-induction and enzyme-inhibition in the rat. Br. J. Pharmacol. 81:1984;557-562.
10. Schary W.L., Rowland M. Protein binding and hepatic clearance: studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation. J. Pharmacokinet. Biopharm. 11:1983;225-243.
11. Nation R.L., Peng G.W., Chiou W.L. Simple, rapid and micro high-pressure liquid chromatographic method for the simultaneous determination of tolbutamide and carboxy tolbutamide in plasma. J. Chromatogr. 146:1978;121-131.
12. Breimer D.D. Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin. Pharmacokinet. 8:1983;371-377.
13. Ashforth E.I. L, Carlile D.J., Chenery R., Houston J.B. Prediction of in vivo disposition from in vitro systems: Clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J. Pharmacol. Exp. Ther. 274:1995;761-766.
14. Belanger P.M., St. Hilaire S. The characteristics of the microsomal hydroxylation of tolbutamide. Can. J. Physiol. Pharmacol. 69:1991;400-405.
15. Doecke C.J., Veronese M.E., Pond S.M., Miners J.O., Birkett D.J., Sansom L.N., McManus M.E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 31:1991;125-130.
16. Veronese M.E., McManus M.E., Lanpattarakasem P., Birkett D.J. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and purified forms of cytochrome P-450. Drug Metab. Dispos. 18:1990;356-361.
17. St. Hilaire S., Belanger P.M. Simultaneous determination of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: Application to pharmacokinetic studies of tolbutamide in the rat. J. Pharmaceut. Sci. 78:1989;863-866.
18. Knodell R.G., Guengerich F.P., Hall S.D., Wilkinson G.R. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P450 involved in the methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241:1987;1112-1119.
19. Shibasaki J., Sasaki H., Nakamura J., Makaya O., Konishi R. High performance liquid chromatographic determination of oxidized derivatives of tolbutamide in rat blood and urine. Chem. Pharm. Bull. 33:1985;4610-4613.
20. Zecca L., Pinelli L., Trivulzio S., Tofanetti O., Colombo R. Determination of glibenclamide, chloropropamide and tolbutamide in plasma by high performance liquid chromatography with ultraviolet detection. J. Chromatogr. 339:1985;203-209.
21. Knight J.B., Matin S.B. Use of a solid sampler in chemical ionization mass spectrometry for determination of compounds unstable under gas liquid chromatographic conditions: Analysis of tolbutamide from biological fluid. Analyt. Lett. 7:1974;529-537.
22. Matin S.B., Knight J.B. Use of solid probe chemical ionization mass spectrometry and gas chromatography chemical ionization mass spectrometry in quantitation of drugs in biological fluids: Determination of tolbutamide and its metabolites in human plasma. Biomed. Mass Spect. 1:1974;323-328.
23. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 72:1976;248-254.
24. Siest G., Batt A.M., Fournel-Gigleux S., Galteau M.M., Wellman-Bednawska M., Minn A., Costesec A.A. Induction of plasma and tissue enzymes by drugs: Significance in toxicological studies. Xenobiotica. 18(supplement 1):1988;21-34.
25. Pond S.M., Birkett D.J., Wade D.N. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin. Pharmacol. Ther. 22:1977;573-579.
26. Miners J.O., Smith K.J., Robson R.A., McManus M.E., Veronese M.E., Birkett D.J. Tolbutamide hydroxylation by human liver microsomes: Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37:1988;1137-1144.
27. Purba H.S., Back D.J., Orme M.L. Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors. Br. J. Clin. Pharmacol. 24:1987;230-234.